Chargement en cours...
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
BACKGROUND: Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the events of disease progression (but...
Enregistré dans:
| Publié dans: | J Immunother Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021890/ https://ncbi.nlm.nih.gov/pubmed/33795385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002114 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|